Table 2.
Association between the clinicopathological characteristics and prognosis of patients with gastric carcinoma.
| Variables | 5-year survival (%) | MST (months) | Log-rank P | |
|---|---|---|---|---|
| Sex | 0.54 | |||
| Male | 41.5 | 35.2 | ||
| Female | 37.3 | 26.2 | ||
|
| ||||
| Age | <0.01 | |||
| <70 | 45.4 | 42.2 | ||
| ≥70 | 26.9 | 24.3 | ||
|
| ||||
| T stage | <0.01 | |||
| T1 | 50.0 | 50.3† | ||
| T2 | 77.1 | 48.8† | ||
| T3 | 52.3 | 69.3 | ||
| T4 | 23.9 | 22.3 | ||
|
| ||||
| N stage | <0.01 | |||
| N0 | 71.9 | 75.2† | ||
| N1 | 58.2 | 72.2 | ||
| N2 | 38.6 | 27.3 | ||
| N3 | 20.2 | 17.1 | ||
|
| ||||
| Differentiation | <0.01 | |||
| Middle | 58.6 | 72.2 | ||
| Low | 35.9 | 26.9 | ||
|
| ||||
| Type | 0.25 | |||
| Adenocarcinoma and others | 42.3 | 31.4 | ||
| Signet-ring cell | 25.6 | 28.2 | ||
|
| ||||
| Size | 0.08 | |||
| <5 cm | 45.4 | 42.6 | ||
| ≥5 cm | 38.6 | 26.9 | ||
|
| ||||
| Lymph vascular invasion | <0.01 | |||
| No | 57.0 | 72.18 | ||
| Yes | 35.8 | 26.94 | ||
|
| ||||
| Neural invasion | <0.01 | |||
| No | 64.3 | 83.15 | ||
| Yes | 31.8 | 24.48 | ||
|
| ||||
| Chemotherapy | <0.01 | |||
| No | 32.4 | 22.28 | ||
| Yes | 51.1 | 83.15 | ||
|
| ||||
| MMP-7 | 0.39 | |||
| — | 41.9 | 35.58 | ||
| + | 37.8 | 24.81 | ||
|
| ||||
| TIMP-1 | 0.71 | |||
| — | 41.5 | 35.15 | ||
| + | 38.1 | 27.27 | ||
|
| ||||
| TIMP-1&MMP-7 | 0.18 | |||
| Both − | 41.7 | 30.82 | ||
| −/+ or +/− | 41.9 | 42.09 | ||
| Both + | 30.0 | 17.38 | ||
|
| ||||
| TIMP-1&MMP-7 | 0.07 | |||
| Not both + | 41.7 | 37.19 | ||
| Both + | 30.0 | 17.38 | ||
†Mean survival time was provided when MST could not be calculated; MST: median survival time, months; −: negative expression; +: positive expression; both −: patients whose tumour tissue expressed neither MMP-7 nor TIMP-1; −/+: patients whose tumour tissue expressed only TIMP-1; +/−: patients whose tumour tissue expressed only MMP-7; both +: patients whose tumour tissue expressed both MMP-7 and TIMP-1.